IS6086A - Aðferð við að meðhöndla hvítblæði - Google Patents

Aðferð við að meðhöndla hvítblæði

Info

Publication number
IS6086A
IS6086A IS6086A IS6086A IS6086A IS 6086 A IS6086 A IS 6086A IS 6086 A IS6086 A IS 6086A IS 6086 A IS6086 A IS 6086A IS 6086 A IS6086 A IS 6086A
Authority
IS
Iceland
Prior art keywords
group
alkynyl
alkenyl
host
alkyl
Prior art date
Application number
IS6086A
Other languages
English (en)
Inventor
Gourdeau Henriette
J. Giles Francis
Original Assignee
Shire Biochem Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biochem Inc. filed Critical Shire Biochem Inc.
Publication of IS6086A publication Critical patent/IS6086A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/32—Thymopoietins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/03—Compounds acting on the NO pathway, e.g. nitrososarginine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
IS6086A 1999-03-29 2001-09-26 Aðferð við að meðhöndla hvítblæði IS6086A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12673499P 1999-03-29 1999-03-29
US12681399P 1999-03-30 1999-03-30
PCT/CA2000/000334 WO2000057861A2 (en) 1999-03-29 2000-03-28 Use of cytidine derivatives for the treatment of leukaemia

Publications (1)

Publication Number Publication Date
IS6086A true IS6086A (is) 2001-09-26

Family

ID=26824972

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6086A IS6086A (is) 1999-03-29 2001-09-26 Aðferð við að meðhöndla hvítblæði

Country Status (24)

Country Link
US (3) US6630480B1 (is)
EP (2) EP1165096B1 (is)
JP (1) JP2002540142A (is)
KR (2) KR20020000554A (is)
CN (1) CN1297281C (is)
AT (1) ATE442151T1 (is)
AU (1) AU773437C (is)
BR (1) BR0009378A (is)
CA (1) CA2366012A1 (is)
CZ (1) CZ20013483A3 (is)
DE (1) DE60042921D1 (is)
DK (1) DK1165096T3 (is)
ES (1) ES2333399T3 (is)
HK (1) HK1041828B (is)
HU (1) HUP0201708A3 (is)
IL (3) IL145634A0 (is)
IS (1) IS6086A (is)
MX (1) MXPA01009888A (is)
NO (1) NO323840B1 (is)
NZ (1) NZ529882A (is)
PL (1) PL351500A1 (is)
SK (1) SK13822001A3 (is)
WO (1) WO2000057861A2 (is)
ZA (1) ZA200107963B (is)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114850B2 (en) 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
DE60036700T2 (de) 1999-04-08 2008-07-24 Antisoma Research Ltd. Antiproliferative aktivität von g-reichen oligonukleotiden und verfahren um sie zur bindung an nukleotin zu verwenden
US7960540B2 (en) 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20110178161A1 (en) * 1999-04-08 2011-07-21 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
DE60011637T2 (de) 1999-09-24 2004-11-11 Shire Biochem Inc., Laval Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
AU2002212015B2 (en) * 2000-10-13 2007-01-25 Shire Canada Inc. Dioxolane analogs for improved inter-cellular delivery
ATE450265T1 (de) * 2001-03-23 2009-12-15 Shire Canada Inc Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
WO2002078678A2 (en) * 2001-03-30 2002-10-10 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
US7158517B2 (en) 2001-05-21 2007-01-02 Intel Corporation Method and apparatus for frame-based protocol processing
EP1441733A1 (en) * 2001-11-02 2004-08-04 Shire Biochem Inc. Pharmaceutical compositions for the treatment of leukemia comprising dioxolane nucleosides analogs
US20040192652A1 (en) * 2002-12-06 2004-09-30 Giles Francis J. Pharmaceutical combinations and methods for the treatment of leukemia
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20040248915A1 (en) * 2003-04-25 2004-12-09 Jacques Jolivet Method for administration of troxacitabine
US8932649B2 (en) 2003-11-14 2015-01-13 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds
KR100708016B1 (ko) * 2004-01-20 2007-04-16 한국쓰리엠 주식회사 스탠드의 전후좌우 회전장치
EP1804816B1 (en) * 2004-03-26 2011-12-21 Vion Pharmaceuticals, Inc. Combination therapy comprising cloretazine(tm)
RU2442777C2 (ru) * 2006-01-31 2012-02-20 Эррэй Биофарма Инк. Ингибиторы киназ и способы их применения
CA2647949A1 (en) 2006-03-29 2007-11-08 Array Biopharma Inc. P38 inhibitors and methods of use thereof
WO2008039758A2 (en) * 2006-09-25 2008-04-03 Cambridge Research & Instrumentation, Inc. Sample imaging and classification
ES2842210T3 (es) * 2006-12-21 2021-07-13 Biokine Therapeutics Ltd 4F-benzoil-TN14003 para la movilización de células progenitoras hematopoyéticas con vistas al trasplante
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
CA2698271C (en) 2007-07-25 2016-07-05 Eisai R & D Management Co., Ltd. Multikinase inhibitors for use in the treatment of cancer
WO2009048953A1 (en) * 2007-10-09 2009-04-16 The Trustees Of The University Of Pennsylvania Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells
ES2462517T3 (es) 2009-06-14 2014-05-23 Biokine Therapeutics Ltd. Terapia con péptidos para aumentar los niveles de plaquetas
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
US10682390B2 (en) 2015-07-16 2020-06-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
KR102033920B1 (ko) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 급성 골수성 백혈병을 치료하는 방법
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
WO2019245444A1 (en) 2018-06-21 2019-12-26 Medivir Ab Base-modified cytidine nucleotides for leukemia therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5684164A (en) 1988-04-11 1997-11-04 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US5270315A (en) 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
WO1990015104A2 (en) 1989-06-05 1990-12-13 Eastman Kodak Company Impact resistant polymer blends
US5817667A (en) 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5643935A (en) * 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
KR102127978B1 (ko) * 2014-01-10 2020-06-29 삼성전자주식회사 구조도 생성 방법 및 장치

Also Published As

Publication number Publication date
SK13822001A3 (sk) 2002-02-05
PL351500A1 (en) 2003-04-22
US6630480B1 (en) 2003-10-07
IL145634A (en) 2006-06-11
JP2002540142A (ja) 2002-11-26
EP1165096B1 (en) 2009-09-09
CN1345242A (zh) 2002-04-17
IL173586A0 (en) 2006-07-05
ATE442151T1 (de) 2009-09-15
KR20020000554A (ko) 2002-01-05
AU773437C (en) 2005-02-17
CZ20013483A3 (cs) 2002-04-17
ZA200107963B (en) 2003-01-02
EP1165096A2 (en) 2002-01-02
CN1297281C (zh) 2007-01-31
WO2000057861A2 (en) 2000-10-05
DK1165096T3 (da) 2010-01-25
HK1041828A1 (en) 2002-07-26
WO2000057861A3 (en) 2001-03-08
AU3546600A (en) 2000-10-16
HK1041828B (zh) 2010-04-30
NO20014727L (no) 2001-11-08
BR0009378A (pt) 2002-01-08
NO323840B1 (no) 2007-07-09
KR20050005569A (ko) 2005-01-13
MXPA01009888A (es) 2003-07-21
NO20014727D0 (no) 2001-09-28
US6747036B2 (en) 2004-06-08
US20040192654A1 (en) 2004-09-30
EP2138179A1 (en) 2009-12-30
HUP0201708A3 (en) 2005-02-28
DE60042921D1 (de) 2009-10-22
AU773437B2 (en) 2004-05-27
IL145634A0 (en) 2002-06-30
US20020107225A1 (en) 2002-08-08
NZ529882A (en) 2005-05-27
ES2333399T3 (es) 2010-02-22
HUP0201708A1 (en) 2002-10-28
CA2366012A1 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
IS6086A (is) Aðferð við að meðhöndla hvítblæði
PL354784A1 (en) Certain alkylene diamine-substituted heterocycles
ATE167679T1 (de) Wirkstoffvorläufer von phosphonaten
CO5640039A2 (es) Compuesto de pirazol-amida sustituidos utiles como inhibidores de cinasa
AP2003002824A0 (en) Gyrase inhibitors and uses thereof
DE60130023D1 (de) Behandlung der nebenwirkungen von statinen
DE69711391D1 (de) Verbessertes verfahren zum herstellen von geschützten 3,4-dihydroxybuttersäure estern
WO2002069903A3 (en) Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
ID18143A (id) Penghambat metaloprotease amina siklik tersubstitusi
ES2164241T3 (es) Compuestos pentaciclicos.
ATE224372T1 (de) Substituierte 6-alkylphenanthridine
BR9915555A (pt) Composto, composição e uso de ß - l- (2' ou 3' -azido) - 2', 3' -didesóxi -5-flúor citosina para o tratamento de infecção por vìrus de hepatite b
WO2002078678A3 (en) Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
ATE247655T1 (de) Dreifachsubstituierte thioxanthine
DE69930678D1 (de) Azidoderivate von beta-l-2'-nukleosiden zur hiv-infektionsbehandlung
ES2173634T3 (es) Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf.